Episode 878: Compensations Tell Short Sellers Everything ｜ Anavex Stock： Exposing Faked Trial

In this episode, Martin discusses how executive compensation structures can inform short sellers about a company’s priorities and potential red flags. He also examines Anavex’s stock and reviews concerns that have been raised about its clinical trial data, explaining how he interprets the available information from an investor’s perspective.